Liu Tao-Hua, Chen Li-Hua, Wan Qi-Quan
Department of Pediatrics, The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan Province, China.
Department of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan Province, China.
World J Gastroenterol. 2025 Feb 28;31(8):98415. doi: 10.3748/wjg.v31.i8.98415.
Liver transplant (LT) recipients are susceptible to carbapenem-resistant (CRKP) infections. Comprehensive research addressing the incidence, timing, infection sites, resistance patterns, treatment options, and associated risk factors among LT recipients with CRKP is now lacking.
To assess the incidence, resistance, therapy, and risk factors of CRKP infections post-LT, and to evaluate the impact of them on prognosis.
A retrospective study was conducted, including 430 consecutive patients who underwent LT between January 2015 and June 2023. This study aimed to investigate the risk factors for CRKP infections and their influence on outcomes using logistic regression analysis.
Among the 430 patients who underwent LT, 20 (4.7%) experienced at least one documented CRKP infection within 3 months post-transplantation. The median time from LT to the onset of CRKP infections was 6.5 days. The lungs and bloodstream were the most common sites of CRKP infections. CRKP isolates were relatively susceptible to ceftazidime/avibactam (93.7%), polymyxin B (90.6%), and tigecycline (75.0%) treatment. However, all isolates were resistant to piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, meropenem, and levofloxacin treatment. Recipients with CRKP infections had a mortality rate of 35%, the rate was 12.5% for those receiving ceftazidime/avibactam therapy. Multivariate analysis identified female sex [odds ratio (OR) = 3.306; 95% confidence interval (CI): 1.239-8.822; = 0.017], intraoperative bleeding ≥ 3000 mL (OR = 3.269; 95%CI: 1.018-10.490; = 0.047), alanine aminotransferase on day 1 post-LT ≥ 1500 U/L (OR = 4.370; 95%CI: 1.686-11.326; = 0.002), and post-LT mechanical ventilation (OR = 2.772; 95%CI: 1.077-7.135; = 0.035) as significant variables associated with CRKP. CRKP infections were related to an intensive care unit length (ICU) of stay ≥ 7 days and 6-month all-cause mortality post-LT.
CRKP infections were frequent complications following LT, with poor associated outcomes. Risk factors for post-LT CRKP infections included female sex, significant intraoperative bleeding, elevated alanine aminotransferase levels, and the need for mechanical ventilation. CRKP infections negatively impacted survival and led to prolonged ICU stays.
肝移植(LT)受者易发生耐碳青霉烯类肺炎克雷伯菌(CRKP)感染。目前缺乏针对LT受者中CRKP感染的发病率、时间、感染部位、耐药模式、治疗选择及相关危险因素的全面研究。
评估LT术后CRKP感染的发病率、耐药性、治疗及危险因素,并评估其对预后的影响。
进行一项回顾性研究,纳入2015年1月至2023年6月期间连续接受LT的430例患者。本研究旨在通过逻辑回归分析调查CRKP感染的危险因素及其对结局的影响。
在430例接受LT的患者中,20例(4.7%)在移植后3个月内至少发生1次有记录的CRKP感染。从LT到CRKP感染发作的中位时间为6.5天。肺部和血液是CRKP感染最常见的部位。CRKP分离株对头孢他啶/阿维巴坦(93.7%)、多粘菌素B(90.6%)和替加环素(75.0%)治疗相对敏感。然而,所有分离株对哌拉西林/他唑巴坦、头孢他啶、头孢吡肟、氨曲南、美罗培南和左氧氟沙星治疗均耐药。发生CRKP感染的受者死亡率为35%,接受头孢他啶/阿维巴坦治疗的患者死亡率为12.5%。多变量分析确定女性[比值比(OR)=3.306;95%置信区间(CI):1.239 - 8.822;P = 0.017]、术中出血≥3000 mL(OR = 3.269;95%CI:1.018 - 10.490;P = 0.047)、LT术后第1天丙氨酸氨基转移酶≥1500 U/L(OR = 4.370;95%CI:1.686 - 11.326;P = 0.002)和LT术后机械通气(OR = 2.772;95%CI:1.077 - 7.135;P = 0.035)是与CRKP相关的显著变量。CRKP感染与重症监护病房(ICU)住院时间≥7天及LT术后6个月全因死亡率相关。
CRKP感染是LT术后常见的并发症,相关结局较差。LT术后CRKP感染的危险因素包括女性、术中大量出血、丙氨酸氨基转移酶水平升高和需要机械通气。CRKP感染对生存产生负面影响,并导致ICU住院时间延长。